Agios Pharmaceuticals Reports Third Quarter Revenue Growth and EPS Beat
Agios Pharmaceuticals (AGIO) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$1.09, beating estimates by $0.15, while revenue reached $55.39 million, representing a significant 330% increase year-over-year and surpassing consensus by $3.79 million. As of September 30, the company maintains a strong liquidity position with $907 million in cash, cash equivalents, and marketable securities. Despite recent market volatility regarding regulatory review extensions for label expansions, Agios continues to work toward its long-term goal of achieving non-GAAP profitability by 2028.
Tickers: $AGIO
Topics: cash position earnings beat financial results revenue growth
Read the full article at Seeking Alpha
Part of the story Transcat Reports Q2 Earnings Beat with $97.1 Million Revenue (9 articles)